Suppr超能文献

对孤立肾肿瘤保肾手术中细胞减灭术与非细胞减灭术管理策略的比较。

A comparison of cytoreductive and non-cytoreductive management strategies for nephron-sparing approaches to tumours in solitary kidneys.

机构信息

Lister Hospital, UK.

Mount Vernon Hospital, UK.

出版信息

Ann R Coll Surg Engl. 2022 Jul;104(7):548-552. doi: 10.1308/rcsann.2021.0251. Epub 2021 Dec 3.

Abstract

INTRODUCTION

Tumours in a solitary kidney pose challenges in management. Metastatic tumours and those in difficult locations complicate treatment further. The advent of immunotherapy has shed new light on the management of such tumours. We present a series of three cases treated with nephron-sparing surgery following neoadjuvant immunotherapy and compare the outcomes with patients who underwent robotic partial nephrectomy in a solitary kidney.

METHODS

We present the outcomes of three patients with solitary kidney tumours who underwent delayed nephron-sparing surgery following good response to immunotherapy. All patients had solitary kidney following a previous nephrectomy, two of which were nonmetastatic but, due to size/location, not amenable to primary treatment; the third patient had metastatic disease and responded to immunotherapy. Two patients underwent robotic partial nephrectomy and one opted for cryotherapy. We compared the preoperative, intraoperative and postoperative parameters of the two patients who underwent robotic cytoreductive partial with patients who underwent robotic partial nephrectomy in a solitary kidney.

RESULTS

Out of 231 partial nephrectomy patients in our centre, 2 underwent cytoreductive partial nephrectomy and 5 underwent solitary partial nephrectomy. There was no statistically significant difference in the patient demographics in the two groups. Patients in both groups had comparable operative time, warm ischaemia time, blood loss and length of stay. Two of the five patients in the non-cytoreductive robotic partial nephrectomy had Clavien Dindo 1 complications compared with one patient in the robotic cytoreductive partial nephrectomy group. This was not statically significant.

CONCLUSION

Neoadjuvant immunotherapy can play a valuable role in shrinking renal tumours in solitary kidneys to facilitate robotic partial nephrectomies. There were no significant differences in the intra- and postoperative parameters in patients who underwent cytoreductive partial nephrectomy when compared with patients undergoing robotic solitary partial nephrectomy.

摘要

介绍

孤立肾中的肿瘤在管理方面带来挑战。转移性肿瘤和位于困难位置的肿瘤使治疗更加复杂。免疫疗法的出现为这类肿瘤的治疗带来了新的曙光。我们报告了三例接受新辅助免疫治疗后行保留肾单位手术治疗的病例,并将其结果与接受机器人辅助单肾部分切除术的患者进行比较。

方法

我们报告了三例接受新辅助免疫治疗后行保留肾单位手术治疗的孤立肾肿瘤患者的结果。所有患者均因先前的肾切除术而只有一个肾脏,其中两个患者的肿瘤虽无转移,但由于大小/位置,不适合进行初始治疗;第三个患者患有转移性疾病并对免疫治疗有反应。两名患者接受了机器人部分肾切除术,一名患者选择了冷冻疗法。我们比较了两名接受机器人减瘤性部分肾切除术的患者与在孤立肾中接受机器人部分肾切除术的患者的术前、术中及术后参数。

结果

在我们中心的 231 例部分肾切除术患者中,有 2 例行减瘤性部分肾切除术,5 例行单肾部分切除术。两组患者的人口统计学特征无统计学差异。两组患者的手术时间、热缺血时间、出血量和住院时间无统计学差异。5 例非减瘤性机器人部分肾切除术后,有 2 例患者出现 Clavien Dindo 1 级并发症,而减瘤性机器人部分肾切除术后,仅 1 例患者出现此类并发症,这无统计学差异。

结论

新辅助免疫疗法可以在孤立肾中缩小肿瘤,为机器人部分肾切除术提供便利。与接受机器人单肾部分切除术的患者相比,行减瘤性部分肾切除术的患者的围手术期参数无显著差异。

相似文献

1
A comparison of cytoreductive and non-cytoreductive management strategies for nephron-sparing approaches to tumours in solitary kidneys.
Ann R Coll Surg Engl. 2022 Jul;104(7):548-552. doi: 10.1308/rcsann.2021.0251. Epub 2021 Dec 3.
5
6
Clinical outcomes of repeat partial nephrectomy compared to initial partial nephrectomy of a solitary kidney.
Int J Clin Oncol. 2020 Jun;25(6):1155-1162. doi: 10.1007/s10147-020-01633-w. Epub 2020 Feb 17.
8
Comparison of perioperative, renal and oncologic outcomes in robotic-assisted versus open partial nephrectomy.
ANZ J Surg. 2018 Mar;88(3):E194-E199. doi: 10.1111/ans.14154. Epub 2017 Sep 18.
9
Repeat Robotic Partial Nephrectomy: Characteristics, Complications, and Renal Functional Outcomes.
J Endourol. 2016 Nov;30(11):1219-1226. doi: 10.1089/end.2016.0517. Epub 2016 Oct 20.
10
Nephron-sparing surgery for renal cell carcinoma in the solitary kidney.
Scand J Urol Nephrol. 2007;41(1):10-3. doi: 10.1080/00365590600911225.

本文引用的文献

1
The current role for adjuvant and neoadjuvant therapy in renal cell cancer.
Curr Opin Urol. 2019 Nov;29(6):636-642. doi: 10.1097/MOU.0000000000000666.
2
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med. 2019 Mar 21;380(12):1103-1115. doi: 10.1056/NEJMoa1816047. Epub 2019 Feb 16.
3
Evaluation of axitinib to downstage cT2a renal tumours and allow partial nephrectomy: a phase II study.
BJU Int. 2019 May;123(5):804-810. doi: 10.1111/bju.14581. Epub 2018 Nov 20.
4
Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma.
Expert Opin Biol Ther. 2018 Sep;18(9):947-957. doi: 10.1080/14712598.2018.1513485. Epub 2018 Aug 30.
5
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.
6
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.
J Clin Oncol. 2017 Dec 1;35(34):3851-3858. doi: 10.1200/JCO.2016.72.1985. Epub 2017 Jul 5.
7
8
A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma.
J Urol. 2015 Aug;194(2):297-303. doi: 10.1016/j.juro.2015.03.096. Epub 2015 Mar 23.
9
Kidney cancer: progress and controversies in neoadjuvant therapy.
Nat Rev Urol. 2014 May;11(5):254-5. doi: 10.1038/nrurol.2014.89. Epub 2014 Apr 22.
10
Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.
Eur Urol. 2014 Nov;66(5):874-80. doi: 10.1016/j.eururo.2014.01.035. Epub 2014 Feb 7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验